NCT05627752View on ClinicalTrials.gov

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate CancerCastrate Resistant Prostate Cancer
Interventions
DRUG

Enzalutamide 40 MG

Adding Enzalutamide to Docetaxel chemotherapy

DRUG

Docetaxel injection

Docetaxel chemotherapy

Trial Locations (2)

430071

RECRUITING

Zhonghua Yang, Wuhan

RECRUITING

Zhonghua Yang, Wuhan

All Listed Sponsors
lead

Zhongnan Hospital

OTHER